Cardiac Biomarkers Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What CAGR Will the Cardiac Biomarkers Market Achieve During 2025–2034, and What Does It Indicate?
The market for cardiac biomarkers has seen considerable growth in the past few years. The market, which was valued at $18.99 billion in 2024, is projected to reach $21.32 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. The historic surge in growth can be related to factors such as increased spending in healthcare, endorsement and regulatory aid from the FDA, an aging demographic, increased awareness initiatives, the advent of highly sensitive troponin tests, and a rise in cardiovascular conditions.
In the coming years, the cardiac biomarkers market is projected to experience substantial growth, estimated to reach a valuation of “$36.51 billion” by 2029, growing at a compound annual growth rate (CAGR) of 14.4%. This growth during the forecast period could be attributed to various factors including, increasing prevalence of chronic diseases, a heightened focus on early diagnosis of diseases, growth in the aged population, advancement in emerging markets, and a growing interest in biomarker panels. Forecast period trends comprise patient-centric healthcare approaches, application of AI and machine learning in healthcare, the integration of digital health, technological breakthroughs in discovering biomarkers, the use of multi-marker panels, and the implementation of liquid biopsy in cardiovascular medicine.
What Are the Primary Drivers Supporting the Growth of the cardiac biomarkers Market?
The cardiac biomarker market is anticipated to experience significant growth due to the increasing occurrence of cardiovascular disorders. Diseases impacting the heart and blood vessels – like coronary artery disease, heart failure, and stroke – fall under the umbrella of cardiovascular disorders. When the body encounters conditions such as myocardial infarction (heart attack), heart failure, and arrhythmias, cardiac biomarkers are dispatched to the bloodstream. Laboratory tests can then measure and provide crucial diagnostic and prognostic data regarding these biomarkers. A case in point, in September 2024, the UK-based cardiovascular research charity – the British Heart Foundation – disclosed that, in the UK alone, around 7.6 million people are grappling with heart and circulatory diseases, including an estimated 4 million men and 3.6 million women. These diseases account for nearly a 27-percent death rate in the UK, which translates to more than 170,000 deaths per year, or approximately 480 deaths daily; essentially, one death every three minutes. Given these circumstances, the cardiac biomarker market is being propelled by the growing prevalence of cardiovascular disorders.
Explore Comprehensive Insights Into The Global Cardiac Biomarkers Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp
Who Are the Key Firms Paving the Way for Growth in the Cardiac Biomarkers Market?
Major companies operating in the cardiac biomarkers market include:
• bioMerieux Inc._x000D_
• Bio-Rad Laboratories_x000D_
• F. Hoffmann-La Roche AG_x000D_
• Siemens AG_x000D_
• Thermo Fisher Scientific Inc._x000D_
What Are the Most Influential Trends Currently Shaping the Cardiac Biomarkers Market?
Technological innovation stands out as one major trend becoming increasingly popular within the cardiac biomarker market. Companies involved in this market are leveraging novel technologies to maintain their competitiveness. For instance, China’s Mindray, a medical device company, introduced new high-sensitivity cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023 to improve cardiovascular disease diagnosis and management. The hs-cTnI biomarker is critical in pinpointing myocardial injury, demonstrating remarkable detection capabilities and negligible imprecision, hence its value in early screening and risk evaluation in instances such as Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP has cemented its place as a reliable indicator for heart failure, assisting in its detection and management—particularly due to its high accuracy and minimal interference with commonly administered heart medication. Collectively, these biomarkers greatly enhance clinical decision-making for emergency cardiovascular situations.
Secure Your Global Cardiac Biomarkers Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report
Which Key Segments of the Cardiac Biomarkers Market Are Poised for Growth and Innovation?
The cardiac biomarkers market covered in this report is segmented –
1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics
Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers
Which Regions Are Essential for the Growth of the Cardiac Biomarkers Market?
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Is the Definition of the Cardiac Biomarkers Market Impacting Future Growth?
Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases.
Browse Through More Similar Reports By The Business Research Company:
Cardiac Assist Devices And Equipment Global Market Report 2024
Cardiovascular Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report
Cardiac Valve Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
